Spots Global Cancer Trial Database for Efficacy of Aprepitant (Emend®) in Children
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy of Aprepitant (Emend®) in Children
Official Title: Efficacy of Aprepitant (Emend®) in Children Receiving Highly Emetogenic Chemotherapy
Study ID: NCT01661335
Study Description
Brief Summary: The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
Detailed Description: 1.1 Primary Aim To determine the efficacy of aprepitant (Emend®) in preventing and reducing chemotherapy-induced nausea and vomiting (CINV) when added to standard antiemetic drug regimens for children receiving highly emetogenic chemotherapy. The working hypothesis will be that standard therapy + aprepitant is superior at preventing CINV than standard therapy + placebo. 1.2 Secondary Aim To evaluate the safety and toxicity of aprepitant (Emend®) in children receiving highly emetogenic chemotherapy when compared to standard antiemetic therapy + placebo.
Eligibility
Minimum Age: 6 Months
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States
Contact Details
Name: Rene McNall-Knapp, MD
Affiliation: University of Oklahoma
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
